遺伝性血管性浮腫の世界市場レポート 2025年

遺伝性血管性浮腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で39億3,000万米ドルに成長します。予測期間中の成長の要因としては、希少疾患の有病率の増加、医療費の増加、非営利団体による支援の拡大、遺伝性血管性浮腫に対する意識の高まり、早期診断への注目の高まりなどが挙げられます。予測期間における主要動向としては、技術革新、新しい治療法の開発、新薬の導入、診断ツールの進歩、遺伝子検査の進歩などが挙げられます。

希少疾患の有病率の増加が、今後数年間の遺伝性血管性浮腫（HAE）市場の成長を牽引すると予想されます。希少疾患は、しばしば希少疾病と呼ばれ、人口のごく一部に影響を及ぼしますが、その有病率の上昇は、医療研究の進歩、人口動態の変化、環境の変化などの要因に起因しています。遺伝性血管性浮腫は注目すべき希少疾病であり、生命を脅かす可能性のある腫脹エピソードのため、専門的な治療と認知の必要性を強調しています。その遺伝的性質と希少性により、早期診断と標的治療が患者の転帰を改善するために極めて重要です。Rare Disease Advisorによると、2022年6月現在、HAEは約5万人に1人の割合で発症し、有病率は1万人に1人から15万人に1人と推定されています。米国では、HAEのエピソードは年間約1万5,000～3万件の救急外来受診を占めています。その結果、希少疾患の症例数の増加が遺伝性血管性浮腫市場の拡大に拍車をかけています。

遺伝性血管性浮腫市場の主要企業は、患者により便利で効果的なオンデマンド治療ソリューションを提供するため、経口血漿カリクレイン阻害剤などの画期的な製品の開発に取り組んでいます。これらの阻害剤は、血漿カリクレインを阻害することで、遺伝性血管性浮腫治療の中心となるブラジキニンの過剰産生を防ぐ働きをします。例えば、2024年9月、米国の製薬会社であるカルビスタ・ファーマシューティカルズ社は、経口血漿カリクレイン阻害剤であるセベトラルスタットの新薬承認申請（NDA）がFDAに受理されたと発表しました。Sebetralstatは、12歳以上の成人と小児患者における遺伝性血管性浮腫発作のオンデマンド治療として設計されています。今回のNDA受理は、本薬の承認と商業化に向けた重要な一歩となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の遺伝性血管性浮腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の遺伝性血管性浮腫市場：成長率分析
• 世界の遺伝性血管性浮腫市場の実績：規模と成長、2019～2024年
• 世界の遺伝性血管性浮腫市場の予測：規模と成長、2024～2029年、2034年
• 世界の遺伝性血管性浮腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の遺伝性血管性浮腫市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 遺伝性血管性浮腫タイプI
• 遺伝性血管性浮腫タイプII
• 世界の遺伝性血管性浮腫市場治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 予防
• オンデマンド
• 世界の遺伝性血管性浮腫市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• C-1エステラーゼ阻害剤
• ブラジキニン受容体拮抗薬
• カリクレイン阻害剤
• その他
• 世界の遺伝性血管性浮腫市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮下
• 静脈内
• 経口
• 世界の遺伝性血管性浮腫市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の遺伝性血管性浮腫市場、遺伝性血管性浮腫タイプIのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• C1インヒビター欠損症
• C1インヒビターレベルの低下
• C1インヒビター機能の低下
• 世界の遺伝性血管性浮腫市場、遺伝性血管性浮腫タイプIIのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 正常C1インヒビターレベル
• 機能不全のC1インヒビター
• SERPING1遺伝子の遺伝子変異

第7章 地域別・国別分析

• 世界の遺伝性血管性浮腫市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の遺伝性血管性浮腫市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 遺伝性血管性浮腫市場：競合情勢
• 遺伝性血管性浮腫市場：企業プロファイル
  • Intellia Therapeutics Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Otsuka Pharmaceutical Co. Ltd.
  • CSL Limited

第31章 その他の大手企業と革新的企業

• Cipla Limited
• BioMarin Pharmaceutical Inc.
• Ionis Pharmaceuticals Inc.
• BioCryst Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Spark Therapeutics Inc.
• Pharming Group N.V.
• Pharvaris N.V.
• Astria Therapeutics Inc.
• CENTOGENE N.V.
• KalVista Pharmaceuticals Inc.
• ADARx Pharmaceuticals Inc.
• Adverum BIoTechnologies Inc.
• Attune Pharmaceuticals Inc.
• Lev Pharmaceuticals Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 遺伝性血管性浮腫市場、2029年：新たな機会を提供する国
• 遺伝性血管性浮腫市場、2029年：新たな機会を提供するセグメント
• 遺伝性血管性浮腫市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Hereditary angioedema (HAE) is a rare genetic condition marked by recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways, resulting from a deficiency or dysfunction of C1 esterase inhibitor. This disorder is caused by genetic mutations affecting the complement system, leading to an overproduction of bradykinin. HAE can be life-threatening if it causes airway swelling, which requires immediate treatment with C1 inhibitor replacement or therapies targeting bradykinin.

The primary types of hereditary angioedema are type I and type II. Type I HAE, the most common form, is caused by a deficiency of C1 esterase inhibitor (C1-INH), resulting in uncontrolled bradykinin production and repeated episodes of swelling. Treatment for HAE is generally categorized into prophylactic and on-demand approaches, utilizing various drug classes such as C1 esterase inhibitors, bradykinin receptor antagonists, kallikrein inhibitors, and others. These treatments are delivered through different methods, including subcutaneous, intravenous, and oral routes, and are available via hospital pharmacies, retail pharmacies, and online pharmacies.

The hereditary angioedema market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema market statistics, including the hereditary angioedema industry global market size, regional shares, competitors with the hereditary angioedema market share, detailed hereditary angioedema market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema industry. This hereditary angioedema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hereditary angioedema market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to factors such as the rising prevalence of hereditary angioedema, increased investment in research and development, a higher number of drug approvals, growing product approvals, and an increase in disposable income.

The hereditary angioedema market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of rare diseases, rising medical expenditure, greater support from non-profit organizations, heightened awareness of hereditary angioedema, and a growing focus on early diagnosis. Key trends in the forecast period include technological innovations, the development of new therapies, the introduction of new drugs, advancements in diagnostic tools, and progress in genetic testing.

The increasing prevalence of rare diseases is expected to drive the growth of the hereditary angioedema (HAE) market in the coming years. Rare diseases, often referred to as orphan diseases, affect a small segment of the population, and their rising prevalence can be attributed to factors such as advancements in medical research, demographic shifts, and environmental changes. Hereditary angioedema, a notable rare disease, underscores the need for specialized treatments and awareness due to its potentially life-threatening swelling episodes. Its genetic nature and rarity make early diagnosis and targeted therapies crucial for better patient outcomes. According to Rare Disease Advisor, as of June 2022, HAE affects around 1 in 50,000 individuals, with prevalence estimates ranging from 1 in 10,000 to 1 in 150,000. In the U.S., HAE episodes account for approximately 15,000 to 30,000 emergency room visits annually. As a result, the growing number of rare disease cases is fueling the expansion of the hereditary angioedema market.

Leading companies in the hereditary angioedema market are working on developing groundbreaking products, such as oral plasma kallikrein inhibitors, to offer more convenient and effective on-demand treatment solutions for patients. These inhibitors work by blocking plasma kallikrein to prevent excessive production of bradykinin, which is central to treating hereditary angioedema. For example, in September 2024, KalVista Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, announced that the FDA had accepted its new drug application (NDA) for sebetralstat, an oral plasma kallikrein inhibitor. Sebetralstat is designed for on-demand treatment of hereditary angioedema attacks in both adult and pediatric patients aged 12 and older. The NDA acceptance marks an important step towards the drug's potential approval and commercialization.

In July 2023, BioCryst Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, partnered with Er-Kim Pharmaceuticals to commercialize ORLADEYO (berotralstat) in Turkey. This collaboration aims to improve access to ORLADEYO for hereditary angioedema patients in Turkey while expanding BioCryst's presence in the global rare disease market. Er-Kim Pharmaceuticals is a Turkish company dedicated to the development, manufacturing, and marketing of high-quality medicines across various therapeutic areas.

Major players in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., and Lev Pharmaceuticals Inc.

North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary angioedema report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hereditary angioedema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hereditary angioedema market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, acute attack management, and long-term prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema market also includes sales of plasma-derived products, biologics, and therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Angioedema Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary angioedema market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary angioedema ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary angioedema market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hereditary Angioedema Type I; Hereditary Angioedema Type II
• 2) By Treatment Type: Prophylaxis; On-demand
• 3) By Drug Class: C-1 Esterase Inhibitors; Bradykynin Receptor Antagonist; Kallikrein Inhibitors; Other Drug Classes
• 4) By Route Of Administration: Subcutaneous; Intravenous; Oral
• 5) By Distribution channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency; Low C1-Inhibitor Levels; Reduced C1-Inhibitor Function
• 2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels; Dysfunctional C1-Inhibitor; Genetic Mutations In SERPING1 Gene
• Companies Mentioned: Intellia Therapeutics Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Otsuka Pharmaceutical Co. Ltd.; CSL Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hereditary Angioedema Market Characteristics

3. Hereditary Angioedema Market Trends And Strategies

4. Hereditary Angioedema Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hereditary Angioedema Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hereditary Angioedema PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hereditary Angioedema Market Growth Rate Analysis
• 5.4. Global Hereditary Angioedema Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hereditary Angioedema Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hereditary Angioedema Total Addressable Market (TAM)

6. Hereditary Angioedema Market Segmentation

• 6.1. Global Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hereditary Angioedema Type I
• Hereditary Angioedema Type II
• 6.2. Global Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prophylaxis
• On-demand
• 6.3. Global Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• C-1 Esterase Inhibitors
• Bradykynin Receptor Antagonist
• Kallikrein Inhibitors
• Other Drug Classes
• 6.4. Global Hereditary Angioedema Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• Oral
• 6.5. Global Hereditary Angioedema Market, Segmentation By Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Hereditary Angioedema Market, Sub-Segmentation Of Hereditary Angioedema Type I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• C1-Inhibitor Deficiency
• Low C1-Inhibitor Levels
• Reduced C1-Inhibitor Function
• 6.7. Global Hereditary Angioedema Market, Sub-Segmentation Of Hereditary Angioedema Type II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal C1-Inhibitor Levels
• Dysfunctional C1-Inhibitor
• Genetic Mutations In SERPING1 Gene

7. Hereditary Angioedema Market Regional And Country Analysis

• 7.1. Global Hereditary Angioedema Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hereditary Angioedema Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Angioedema Market

• 8.1. Asia-Pacific Hereditary Angioedema Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Angioedema Market

• 9.1. China Hereditary Angioedema Market Overview
• 9.2. China Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Angioedema Market

• 10.1. India Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Angioedema Market

• 11.1. Japan Hereditary Angioedema Market Overview
• 11.2. Japan Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Angioedema Market

• 12.1. Australia Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Angioedema Market

• 13.1. Indonesia Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Angioedema Market

• 14.1. South Korea Hereditary Angioedema Market Overview
• 14.2. South Korea Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Angioedema Market

• 15.1. Western Europe Hereditary Angioedema Market Overview
• 15.2. Western Europe Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Angioedema Market

• 16.1. UK Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Angioedema Market

• 17.1. Germany Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Angioedema Market

• 18.1. France Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Angioedema Market

• 19.1. Italy Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Angioedema Market

• 20.1. Spain Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Angioedema Market

• 21.1. Eastern Europe Hereditary Angioedema Market Overview
• 21.2. Eastern Europe Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Angioedema Market

• 22.1. Russia Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Angioedema Market

• 23.1. North America Hereditary Angioedema Market Overview
• 23.2. North America Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Angioedema Market

• 24.1. USA Hereditary Angioedema Market Overview
• 24.2. USA Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Angioedema Market

• 25.1. Canada Hereditary Angioedema Market Overview
• 25.2. Canada Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Angioedema Market

• 26.1. South America Hereditary Angioedema Market Overview
• 26.2. South America Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Angioedema Market

• 27.1. Brazil Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Angioedema Market

• 28.1. Middle East Hereditary Angioedema Market Overview
• 28.2. Middle East Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Angioedema Market

• 29.1. Africa Hereditary Angioedema Market Overview
• 29.2. Africa Hereditary Angioedema Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hereditary Angioedema Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hereditary Angioedema Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Angioedema Market Competitive Landscape And Company Profiles

• 30.1. Hereditary Angioedema Market Competitive Landscape
• 30.2. Hereditary Angioedema Market Company Profiles
  • 30.2.1. Intellia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. CSL Limited Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Angioedema Market Other Major And Innovative Companies

• 31.1. Cipla Limited
• 31.2. BioMarin Pharmaceutical Inc.
• 31.3. Ionis Pharmaceuticals Inc.
• 31.4. BioCryst Pharmaceuticals Inc.
• 31.5. Arrowhead Pharmaceuticals Inc.
• 31.6. Spark Therapeutics Inc.
• 31.7. Pharming Group N.V.
• 31.8. Pharvaris N.V.
• 31.9. Astria Therapeutics Inc.
• 31.10. CENTOGENE N.V.
• 31.11. KalVista Pharmaceuticals Inc.
• 31.12. ADARx Pharmaceuticals Inc.
• 31.13. Adverum Biotechnologies Inc.
• 31.14. Attune Pharmaceuticals Inc.
• 31.15. Lev Pharmaceuticals Inc

32. Global Hereditary Angioedema Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Angioedema Market

34. Recent Developments In The Hereditary Angioedema Market

35. Hereditary Angioedema Market High Potential Countries, Segments and Strategies

• 35.1 Hereditary Angioedema Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hereditary Angioedema Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hereditary Angioedema Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer